8 January 2021

German biotech Curevac has struck an alliance with Bayer to support the achievement of regulatory approval for its Covid-19 vaccine candidate, CVnCoV, as well as help initiate distribution of the vaccine. Bayer is expected to contribute its expertise in clinical trials, pharmacovigilance, regulatory affairs, medical information, supply chain performance, and backing in certain countries.

Oragenics has entered into a material transfer agreement with Adjuvance Technologies. The agreement centres around Oragenics using Adjuvance’s adjuvant TQL1055 in its Terra CoV-2 vaccine against Covid-19; adjuvants are used to enhance the immunogenicity of the vaccines. This agreement focuses on pre-clinical studies of TQL1055, but Oragenics expects to enter into a licensing agreement for Adjuvance’s adjuvant for clinical studies later in 2021.

Bharat Biotech has announced the completion of the recruitment of 25,800 people for its Phase III efficacy trial for Covaxin, its Covid-19 vaccine candidate. Over 5,000 people have already received both shots of the vaccine in the study and efficacy data is expected in March.

Turkish pharma company Abdi Ibrahim has been granted a license by the country’s health ministry to produce and fill vials of inactive and messenger RNA vaccines against Covid-19. Nezih Barut, the company’s chairman further stated that it was capable of producing 20 million vaccines.

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData
Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.